The 2026 Congress of the International Society of Gynaecological Endocrinology (ISGE) featured a review on optimizing transdermal oestradiol therapy for menopause. The presentation focused on dose, serum levels, and clinical outcomes, emphasizing that menopausal hormone therapy remains the most effective treatment for vasomotor symptoms, genitourinary syndrome of menopause, and osteoporosis prevention.
According to the review, transdermal oestradiol offers advantages over oral therapy, including lower risk of venous thromboembolism and stroke. The recommended starting dose is typically 0.025β0.05 mg/day, adjusted based on symptom relief and serum estradiol levels, aiming for 50β100 pg/mL.
Clinical outcomes discussed included improved quality of life, reduced hot flash frequency, and bone density preservation. The review noted that individualization of therapy is key, with monitoring of serum levels recommended in cases of inadequate response or suspected absorption issues.
